Gilead Sciences (GILD) Net Cash Flow Growth (3y) (2012 - 2026)
Powered by 
Analysis
Gilead Sciences (GILD) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -10.13% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -98.96% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -8.34% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 36.60% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -35.85% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 67.39% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -96.44% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 52.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -98.96% |
| Mar 31, 2026 | 29.14% |
| Dec 31, 2025 | -28.93% |
| Sep 30, 2025 | 309.16% |
| Jun 30, 2025 | -98.46% |
| Mar 31, 2025 | -26.73% |
| Dec 31, 2024 | 71.98% |
| Sep 30, 2024 | 85.37% |
| Jun 30, 2024 | -63.80% |
| Mar 31, 2024 | 10.93% |
| Dec 31, 2023 | 27.02% |
| Sep 30, 2023 | -89.53% |
| Jun 30, 2023 | 30.58% |
| Mar 31, 2023 | 31.51% |
| Dec 31, 2022 | -32.93% |
| Sep 30, 2022 | 26.38% |
| Jun 30, 2022 | 27.78% |
| Mar 31, 2022 | 0.29% |
| Dec 31, 2021 | -33.90% |
| Sep 30, 2021 | -33.52% |